Hormonal contraception and risk of venous thromboembolism
Authors:
O. Ludka; J. Špinar; V. Musil; Z. Pozdíšek
Authors‘ workplace:
Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
Published in:
Vnitř Lék 2010; 56(5): 370-375
Category:
Original Contributions
Overview
Oral contraceptives increase the risk of thromboembolism. Recent studies have indicated that the risk of thromboembolic disease in users of combined oral contraceptive pills varies not only with estrogen dose, but also with the type of gestagen in pills with the same estrogen dose. We describe 8 women from our intensive care unit who developed a deep venous thrombosis while on oral contraceptives. The aim of this article is also to discuss other risk factors for the potential risk of venous tromboembolism in users of combined oral contraceptive.
Key words:
oral hormonal contraception – venous thromboembolism
Sources
1. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301–1336.
2. Noboa S, Mottier D, Oger E. EPI‑GETBO Study Group. Estimation of a potentially preventable fraction of venous thromboembolism: a community‑based prospective study. J Thromb Haemost 2006; 4: 2720–2722.
3. Widimsky J, Maly J, Elias P et al. Doporučení diagnostiky, léčby a prevence plicní embolie, verze 2007. Cor Vasa 2008; 50 (Suppl): 1S25–1S72.
4. Rock J, Garcia CR, Pincus G. Synthetic progestins in the normal human menstrual cycle. Recent Prog Horm Res 1957; 13: 323–339.
5. Inman WH, Vessey MP, Westerholm B et al. Thromboembolic disease and the steroidal kontent of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203–209.
6. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular actions associated with oral contraceptives and a comparison of the safety of 50 and 30 μg estrogen preparations. Br Med J 1980; 280: 1157–1161.
7. Böttiger LE, Boman G, Eklund G et al. Oral Contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 1: 1097–1101.
8. World Health Organisation Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–1588.
9. Jick H, Jick SS, Gurewitch V et al. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–1593.
10. Spitzer WO, Lewis MA, Heinemann L et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case‑control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83–88.
11. EMEA. Committee for Proprietary Medicinal Products (CPMP) public assessment report on combined oral contraceptives and venous thromboembolism. Available from http://www.emea.EU.int/pdfs/human/reggaffair/0220101en.pdf.
12. Vasilakis‑Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427–1429.
13. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five‑year national case‑control study. Contraception 2002; 65: 187–196.
14. Lidegaard Ø, Løkkegaard E, Svendsen AL et al. Hormonal contraception and risk of venous thromboembolism: national follow‑up study. BMJ 2009; 339: 557–560.
15. Čepický P, Cibula D, Dvořák K et al. Doporučení k předpisu kombinované hormonální kontracepce (CC). Aktualizace 2005. Čes Gynekol 2005; 70: 465–468.
16. Dulíček P, Kalousek I. Hormonální antikoncepce a tromboembolická nemoc na konci tisíciletí. Plánování rodiny a reprodukční zdraví 2000; 3: 60–63.
Labels
Paediatric gynaecology Diabetology Endocrinology Gynaecology and obstetrics Internal medicineArticle was published in
Internal Medicine
2010 Issue 5
Most read in this issue
- Familial hypercalcemia and hypophosphatemia: importance in differential diagnosis of disorders in calcium‑ phosphate metabolism
- A review of the effects of prolactin hormone and cytokine on the development and pathogenesis of autoimmune diseases
- Polycystic ovary syndrome and autoimmune diseases
- ILCOR recommendation on signing of automated external defibrillators (AEDs)